ATE293993T1 - Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans - Google Patents

Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans

Info

Publication number: ATE293993T1
Authority: AT; Austria
Prior art keywords: sub; vaccine formulation; formulation; fatty acids; sup
Prior art date: 1999-02-12

Application number

AT00903678T

Other languages

English (en)

Inventor

Ulf Schroeder

Stefan Svenson

Original Assignee

Eurocine Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-12

Filing date

2000-02-09

Publication date

2005-05-15

2000-02-09 Application filed by Eurocine Ab filed Critical Eurocine Ab

2005-05-15 Application granted granted Critical

2005-05-15 Publication of ATE293993T1 publication Critical patent/ATE293993T1/de

Links

239000000203 mixture Substances 0.000 title abstract 6
238000009472 formulation Methods 0.000 title abstract 5
239000002671 adjuvant Substances 0.000 title abstract 3
229960005486 vaccine Drugs 0.000 title abstract 3
235000014113 dietary fatty acids Nutrition 0.000 title abstract 2
229930195729 fatty acid Natural products 0.000 title abstract 2
239000000194 fatty acid Substances 0.000 title abstract 2
150000004665 fatty acids Chemical class 0.000 title abstract 2
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 title 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 abstract 2
230000003053 immunization Effects 0.000 abstract 2
244000005700 microbiome Species 0.000 abstract 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract 1
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 abstract 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract 1
241000187479 Mycobacterium tuberculosis Species 0.000 abstract 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract 1
239000005642 Oleic acid Substances 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
125000000837 carbohydrate group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract 1
229940074096 monoolein Drugs 0.000 abstract 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
235000012424 soybean oil Nutrition 0.000 abstract 1
239000003549 soybean oil Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
229960000814 tetanus toxoid Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

AT00903678T 1999-02-12 2000-02-09 Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans ATE293993T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9900496A SE9900496D0 (sv)	1999-02-12	1999-02-12	Vaccine formulation
PCT/EP2000/001038 WO2000047224A2 (en)	1999-02-12	2000-02-09	Vaccine formulation comprising monoglycerides or fatty acids as adjuvant

Publications (1)

Publication Number	Publication Date
ATE293993T1 true ATE293993T1 (de)	2005-05-15

Family

ID=20414470

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00903678T ATE293993T1 (de)	1999-02-12	2000-02-09	Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans

Country Status (9)

Country	Link
US (1)	US6890540B1 (de)
EP (1)	EP1150713B1 (de)
AT (1)	ATE293993T1 (de)
AU (1)	AU769375B2 (de)
DE (1)	DE60019726T2 (de)
DK (1)	DK1150713T3 (de)
NZ (1)	NZ513129A (de)
SE (1)	SE9900496D0 (de)
WO (1)	WO2000047224A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE480258T1 (de) *	2002-11-26	2010-09-15	Eurocine Vaccines Ab	Neue adjuvant auf der basis von aminen
US7349378B2 (en) *	2003-02-24	2008-03-25	Toshiba America Research, Inc.	Local area network resource manager
US20080044440A1 (en) *	2004-02-18	2008-02-21	Margaret Dunkley	Vaccine Formulated For Administration To Mucosa Of The Lungs
EP1843787B1 (de) *	2005-01-28	2011-11-02	North-West University	Lipid- und distickstoffoxidverbindung als hilfsmittel zur erhöhung der impfstoffeffizienz
US20090023682A1 (en) *	2007-07-19	2009-01-22	Joseph Artiss	Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8916164B2 (en) *	2007-08-29	2014-12-23	Abivax	Methods of enhancing adjuvaticity of vaccine compositions
ES2519475T5 (es)	2008-05-01	2018-07-02	Arecor Limited	Formulación de una proteína
US9968666B2 (en)	2009-06-12	2018-05-15	Vaccine Technologies, Incorporated	Methods and compositions for promoting a cell-mediated immune response
WO2010144797A2 (en)	2009-06-12	2010-12-16	Vaccine Technologies, Incorporated	Influenza vaccines with enhanced immunogenicity and uses thereof
WO2010144794A1 (en)	2009-06-12	2010-12-16	Vaccine Technologies, Incorporated	Baculovirus-expressed fusion polypeptide vaccines with enhanced immunogenicity and uses thereof
CN114010776A (zh)	2010-06-09	2022-02-08	疫苗技术股份有限公司	用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
AU2012253359B2 (en)	2011-05-11	2017-06-08	Children's Medical Center Corporation	Multiple antigen presenting immunogenic composition, and methods and uses thereof
EP2742952A1 (de)	2012-12-17	2014-06-18	Eurocine Vaccines AB	Impfstoffzusammensetzung
CA2900008C (en)	2013-02-07	2025-10-07	Children's Medical Center Corporation	PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4847080A (en) *	1984-03-07	1989-07-11	New York Blood Center, Inc.	Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
JPH0832638B2 (ja) *	1989-05-25	1996-03-29	カイロンコーポレイション	サブミクロン油滴乳剤を含んで成るアジュバント製剤
SE9601158D0 (sv) *	1996-03-26	1996-03-26	Stefan Svenson	Method of producing immunogenic products and vaccines
SE9602280D0 (sv)	1996-06-10	1996-06-10	Pharmatrix Ab	Immunstimulerande lipidformulering
US6350456B1 (en) *	1997-03-13	2002-02-26	Corixa Corporation	Compositions and methods for the prevention and treatment of M. tuberculosis infection
EP1567400A2 (de)	2002-11-26	2005-08-31	Frost Inc.	Zapfenlager für wagenrolle

1999
- 1999-02-12 SE SE9900496A patent/SE9900496D0/xx unknown
2000
- 2000-02-09 DK DK00903678T patent/DK1150713T3/da active
- 2000-02-09 WO PCT/EP2000/001038 patent/WO2000047224A2/en not_active Ceased
- 2000-02-09 DE DE60019726T patent/DE60019726T2/de not_active Expired - Lifetime
- 2000-02-09 US US09/926,002 patent/US6890540B1/en not_active Expired - Fee Related
- 2000-02-09 AU AU25473/00A patent/AU769375B2/en not_active Ceased
- 2000-02-09 AT AT00903678T patent/ATE293993T1/de active
- 2000-02-09 EP EP00903678A patent/EP1150713B1/de not_active Expired - Lifetime
- 2000-02-09 NZ NZ513129A patent/NZ513129A/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO2000047224A2 (en)	2000-08-17
DK1150713T3 (da)	2005-08-29
EP1150713B1 (de)	2005-04-27
US6890540B1 (en)	2005-05-10
DE60019726T2 (de)	2006-04-27
SE9900496D0 (sv)	1999-02-12
NZ513129A (en)	2003-01-31
DE60019726D1 (de)	2005-06-02
AU2547300A (en)	2000-08-29
AU769375B2 (en)	2004-01-22
EP1150713A2 (de)	2001-11-07
WO2000047224A3 (en)	2000-12-14

Legal Events

Date

Code

Title

Description

2006-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1150713

Country of ref document: EP

Publication	Publication Date	Title
ATE293993T1 (de)	2005-05-15	Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans
CY1110140T1 (el)	2015-01-14	Εμβολιασμος με μηνιγγοκοκκικο συζευγμα
DK0777490T3 (da)	2006-09-18	Mutant-enterotoxin, som er effektivt som et ikke-toksisk oralt adjuvans
SE9600716D0 (sv)	1996-02-26	Adhesion inhibitors, preparation comprising them and method for producing them
SE9602280D0 (sv)	1996-06-10	Immunstimulerande lipidformulering
EP0271909A3 (de)	1989-12-06	Triglycerid enthaltende Zusammensetzung
BR0111834A (pt)	2003-07-08	Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
ATE342065T1 (de)	2006-11-15	Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant
DK0584126T3 (da)	1997-10-20	Lanolinderivater som penetrationsfremmende stoffer
FI932759A0 (fi)	1993-06-16	Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
ATE108487T1 (de)	1994-07-15	Herstellung eines desoxyribonucleosids.
WO1993013797A3 (en)	1993-10-28	Detoxified lps-cholera toxin conjugate vaccine for prevention of cholera
SE9601158D0 (sv)	1996-03-26	Method of producing immunogenic products and vaccines
SE0100011D0 (sv)	2001-01-03	Virus vaccine formulation
Tsujimoto et al.	1986	Adjuvant activity of 6-O-acyl-muramyldipeptides to enhance primary cellular and humoral immune responses in guinea pigs: dose-response and local reactions observed with selected compounds
DE60139404D1 (de)	2009-09-10	Parenterale impfstoff-formulierungen und deren verwendung
WO2024173723A3 (en)	2024-10-24	Use of crassocephalum rabens extract in inducing humoral immune response
GB9930862D0 (en)	2000-02-16	Immune response stimulation
佐伯英治 et al.	1989	Effect of Corynebacterium parvum bacterin on artificial immunity against Babesia rodhaini infection in mice.
RU99115191A (ru)	2001-05-20	Инактивированная вакцина против ку-лихорадки
RU93043610A (ru)	1997-02-10	Фармацевтическая композиция для усиления первичной иммуно-реакции у млекопитающих, способ усиления первичной иммуно-реакции и применение интерлейкина-4 для усиления первичной иммуно-реакции у млекопитающих, набор лекарственных средств